Consistent with the positive effects of cAMP elevation in primary melanoma, pharmacological inhibition of EPACs (with ESI-09, a cAMP competitive inhibitor of EPAC and EPAC2) markedly decreased the proliferation of human primary melanoma cells and stimulated the proliferation of metastatic melanoma cells. Here, RAPGEF3 is linked to melanoma.